For Healthcare Professionals

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies


About the study

This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria

  1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Chinese subjects at least 18 years of age at the time of study entry.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  4. Adequate hematological and organ function.
  5. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.
  6. Pathologically confirmed MCL, with documentation of chromosome translocation t(11;14) (q13;q32) and/or overexpression of cyclin D1 in association with other relevant markers (eg, CD5, CD19, CD20, PAX5). Disease had relapsed after or been refractory to previous treatment.
  7. Diagnosis of CLL that meets published diagnostic criteria. Must have received ≥ 1 prior systemic therapies for CLL.
  8. Active disease per iwCLL 2018 criteria that requires treatment. (CLL only)
  9. Other relapsed/refractory B-cell malignancies without stand of care (phase 1 only).


Exclusion criteria

  1. Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject had been disease free for ≥2 years or which would not have limited survival to <2 years.
  2. Significant cardiovascular disease.
  3. Known central nervous system involvement of lymphoma/leukemia or leptomeningeal disease.
  4. Known history of HIV, serologic status reflecting active hepatitis B or C infection.
  5. Major surgery within 4 weeks before first dose of study drugs.
  6. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
  7. Required or received anticoagulation with warfarin or equivalent vitamin K antagonist (eg, phenprocoumon).
  8. Prior exposure to a BCR or BCL-2 inhibitor.
  9. Use of a strong inhibitor or inducer of CYP3A.
  10. Breastfeeding or pregnant.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Phase I: Relapsed or Refractory B-cell Malignancies,Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma,Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

Age (in years)

18 - 130


Phase 1/Phase 2

Participants needed


Est. Completion Date

Dec 29, 2023

Treatment type



AstraZeneca identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.